SCHEMBL13304953

SCHEMBL13304953

Bc1cnn2c(NCc3ccc(NCCOC)nc3)cc(-c3ccccc3)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 7/20 0.49
▸ CDK2 P24941 6/20 0.48
▸ CCNE1 P24864 4/20 0.47
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ POLB P06746 1/20 0.43
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12953175 0.89 CDK2 (0.62) GSK3BCDK2CCNE1
SCHEMBL13146084 0.88 GSK3B (0.49) GSK3BCDK2CCNE1MEN1KMT2A
SCHEMBL13304826 0.81 GSK3B (0.52) GSK3BCDK2CCNE1MEN1KMT2A
SCHEMBL13304888 0.79 CDK2 (0.54) GSK3BCDK2CCNE1MEN1KMT2A
SCHEMBL13305601 0.79 CDK2 (0.54) GSK3BCDK2CCNE1MEN1KMT2A
SCHEMBL13146184 0.77 GSK3B (0.50) GSK3BCDK2CCNE1MEN1KMT2A
SCHEMBL13146048 0.77 GSK3B (0.77) GSK3BCDK2CCNE1
SCHEMBL12953217 0.77 CDK2 (0.62) GSK3BCDK2CCNE1
SCHEMBL13305042 0.77 HRH4 (0.50) GSK3BCDK2CCNE1
SCHEMBL12953041 0.76 CDK2 (0.69) GSK3BCDK2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537116-B1 PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES SCHERING CORP (US) 2010-06-02 — — EP disclosed
Send feedback